IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: A significant 4.2-fold (p < 0.001), 5.2-fold (p < 0.001), and 10.6-fold (p < 0.001) reduced IL-6-stained area was quantified in the apoA-I mixed with CIGB-258 at the molar ratio of 1:0.1, 1:0.5, and 1:1 than the IL-6-stained area observed in the CML injected group, suggesting the effect of apoA-I and CIGB-258 to prevent CML induced IL-6 production.